LRI-funded Scientist Gives Talk About Future of Lupus Treatment
Source: Healio Rheumatology
Talking about potential future therapies, Silverman said new treatment pathways are currently being explored and have demonstrated efficacy in an open-label extension study. A Fc-gamma receptor, SM101 (SuppreMol, GmbH), part of the immunoglobulin G expression pathway, is being explored for lupus nephritis in a Phase 2 clinical trial. Silverman also said PF-04236921 (Pfizer), an interleukin-6 inhibitor, is in a phase 2b randomized clinical trial for patients with SLE. He said a study of eight patients with lupus that has resisted treatment demonstrated promising results from off-label treatment with bortezomib (Velcade, Millennium Pharmaceuticals), a proteasome inhibitor approved for multiple myeloma. Other drugs, including sifalimumab andanifrolumab (AstraZeneca and MedImmune), are also in Phase 2 trials and target interferon.